VELVET (Veltuzumab Various Doses Exploratory Trial), a Randomized, Double Blind, Placebo Controlled, Multicentre, Multinational Phase II Dose Range Finding Trial in Subjects With Moderate to Severe Rheumatoid Arthritis Insufficiently Controlled With Either Methotrexate Alone or Methotrexate Plus Anti-tumour Necrosis Factor Biological Treatment, Comparing 3 Different Subcutaneous Dosages of Anti-CD20 Monoclonal Antibody Veltuzumab to Placebo as an add-on Therapy to Methotrexate.

This is a multi-national, multi-centre, placebo-controlled, double-blind, randomized, 4-arm parallel group trial, comparing three different dose levels (80 mg, 160 mg and 320 mg) of veltuzumab to placebo, administered weekly (days 1, 8, 15 and 22) by subcutaneous (sc) injection to subjects with moderate to severe rheumatoid arthritis (RA) (cumulative veltuzumab doses 320 mg, 640 mg, and 1280 mg, respectively). All subjects will be on continued stable co-medication with methotrexate (MTX).

开始日期2011-08-01

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

EUCTR2010-022378-15-ES / Not yet recruitingN/A

VELVET (Veltuzumab various doses exploratory trial), a randomized, double blind, placebo controlled, multicentre, multinational phase II dose range finding trial in subjects with moderate to severe rheumatoid arthritis insufficiently controlled with either methotrexate alone or methotrexate plus anti-tumour necrosis factor biological treatment, comparing 3 different subcutaneous dosages of anti-CD20 monoclonal antibody veltuzumab to placebo as an add-on therapy to methotrexate. - VELVET

开始日期2011-05-19

申办/合作机构

Nycomed GmbH

100 项与维妥珠单抗相关的临床结果

登录后查看更多信息

100 项与维妥珠单抗相关的转化医学

登录后查看更多信息

100 项与维妥珠单抗相关的专利（医药）

登录后查看更多信息

1,790

项与维妥珠单抗相关的文献（医药）

2024-04-01·Journal of neurology

Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment

Review

作者: Faissner, Simon ; Linker, Ralf A ; Rammohan, Kottil ; Delgado, Silvia R

Abstract:

The recent success of anti-CD20 monoclonal antibody therapies in the treatment of multiple sclerosis (MS) has highlighted the role of B cells in the pathogenesis of MS. In people with MS, the inflammatory characteristics of B-cell activity are elevated, leading to increased pro-inflammatory cytokine release, diminished anti-inflammatory cytokine production and an accumulation of pathogenic B cells in the cerebrospinal fluid. Rituximab, ocrelizumab, ofatumumab, ublituximab and BCD-132 are anti-CD20 therapies that are either undergoing clinical development, or have been approved, for the treatment of MS. Despite CD20 being a common target for these therapies, differences have been reported in their mechanistic, pharmacological and clinical characteristics, which may have substantial clinical implications. This narrative review explores key characteristics of these therapies. By using clinical trial data and real-world evidence, we discuss their mechanisms of action, routes of administration, efficacy (in relation to B-cell kinetics), safety, tolerability and convenience of use. Clinicians, alongside patients and their families, should consider the aspects discussed in this review as part of shared decision-making discussions to improve outcomes and health-related quality of life for people living with MS.

2024-02-01·The Lancet. Haematology

Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study

Article

作者: Panizo, Carlos ; Triguero, Ana ; Sharma, Sunil ; Abrisqueta, Pau ; Banerjee, Lalita ; Bastos-Oreiro, Mariana ; González-Barca, Eva ; Pérez, José María Arguiñano ; Jin, Hyun Yong ; Musick, Lisa ; McMillan, Andrew ; Seymour, Erlene ; Hirata, Jamie ; de Guzman, Jayson ; Miall, Fiona ; Diefenbach, Catherine

BACKGROUND:

Diffuse large B-cell lymphoma comprises nearly 30% of non-Hodgkin lymphoma cases and patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for stem-cell transplantation have few treatment options and poor prognoses. We aimed to determine whether the novel combination of polatuzumab vedotin in combination with rituximab and lenalidomide (Pola+R+Len) would provide a tolerable treatment option with enhanced antitumour response in patients with relapsed or refractory diffuse large B-cell lymphoma.

METHODS:

This completed phase 1b/2, open-label, multicentre, single-arm study (GO29834) evaluated the safety and efficacy of Pola+R+Len in patients with relapsed or refractory diffuse large B-cell lymphoma at 19 sites in three countries (USA, Spain, and UK). Patients (≥18 years old) were eligible for inclusion if they had histologically documented CD20-positive relapsed or refractory diffuse large B-cell lymphoma and Eastern Cooperative Oncology Group performance status of 2 or lower, had received at least one previous line of chemoimmunotherapy, including an anti-CD20 agent, and were ineligible for stem-cell transplantation. The dose-escalation phase (1b) used escalating doses of lenalidomide to find the recommended phase 2 dose. Patients received six 28-day cycles of induction treatment with intravenous rituximab 375 mg/m² and intravenous polatuzumab vedotin 1·8 mg/kg (all cohorts) plus oral lenalidomide at the following doses: 10 mg (cohort A); 15 mg (cohort B); and 20 mg (cohort C). Rituximab and polatuzumab vedotin were administered on day 1 and lenalidomide on days 1-21 of each 28-day cycle. During the dose-expansion phase (2), patients received six 28-day cycles of Pola+R+Len at the recommended phase 2 dose established during dose escalation. In both phases, patients with a complete response or partial response at the end of induction were eligible for post-induction therapy with rituximab 375 mg/m² on day 1 and lenalidomide 10 mg/day on days 1-21 of each 28-day cycle for a maximum of 6 cycles. The primary safety objective of the dose-escalation phase was identification of the maximum tolerated dose through incidence of dose-limiting toxic effects. The primary efficacy outcome of the dose-expansion phase was Independent Review Committee-assessed complete response rate at end of induction, based on PET-CT. Analyses were conducted in the safety population, which included all patients who received at least one dose of any study drug, and the efficacy population, which included all patients who received at least one dose of any study drug at the recommended phase 2 dose. This study is registered with ClinicalTrials.gov, number NCT02600897.

FINDINGS:

Between July 11, 2017 and Feb 3, 2020, 57 patients were enrolled (median age 71 years [IQR 60-75]; 38 [67%] were male and 19 (33%) were female; 47 [82%] were not Hispanic or Latino; and the median previous lines of therapy was 2 [IQR 1-3]). 18 participants were included in phase 1b and 39 were included in phase 2. Phase 1b confirmed a 20 mg recommended phase 2 dose for lenalidomide. After a median follow-up of 11·8 months (IQR 4·7-25·8), the complete response rate, as assessed by the Independent Review Committee, was 31% (90% CI 20-43). The most common grade 3-4 adverse events were neutropenia (35 [61%] of 57) and thrombocytopenia (eight [14%] of 57). Serious adverse events were reported in 23 (40%) of 57 patients and one patient died due to a treatment-related adverse event (neutropenic sepsis).

INTERPRETATION:

Although the combination of Pola+R+Len did not meet the prespecified activity threshold, some patients derived clinical benefit and the regimen had a tolerable safety profile in patients with relapsed or refractory diffuse large B-cell lymphoma.

FUNDING:

Genentech/F Hoffmann-La Roche.

2024-02-01·Multiple sclerosis and related disorders

Ocrelizumab in highly disabled progressive multiple sclerosis patients

Article

作者: Howard, Danielle ; Houtchens, Maria

BACKGROUND:

Ocrelizumab is a commonly used anti-CD20 monoclonal antibody with efficacy in the treatment of both relapsing-remitting (RRMS) and primary progressive (PPMS) multiple sclerosis. Real world use of ocrelizumab in MS patients with higher levels of motor disability requiring a walker or a wheelchair is not well characterized as these populations were excluded from initial studies. Higher levels of disability may be a barrier to treatment access. This study aimed to describe the access to, and tolerability and therapeutic outcomes of ocrelizumab in highly disabled MS patients in a real-world setting.

METHODS:

As part of an ongoing study of ocrelizumab treatment access, barriers, and outcomes in MS patients at the Brigham MS Center, we retrospectively reviewed all patients with an Expanded Disability Status Scale (EDSS) of 6.5 or greater at the time of ocrelizumab initiation. All patients were started on ocrelizumab by their treating providers prior to this study initiation. Patients were excluded for recent rituximab exposure, co-treatment with more than one immunosuppressant, or alternative diagnoses contributing to high EDSS. Data was collected on incidence and severity of side effects while on ocrelizumab, persistence of treatment beyond one year, and MS stabilization versus progression while on this treatment.

RESULTS:

Of the 1219 patients on ocrelizumab between 2017 and 2021, 113 (9.3 %) had EDSS of 6.5 or greater at the time of ocrelizumab initiation. Of the 113, 51 (45.1 %) were excluded: 6 (5.3 %) because they were duplicates or didn't receive ocrelizumab at our center, 25 (22.1 %) due to rituximab treatment in the previous year, 16 (14.2 %) due to lack of at least 1 year of follow up, and 4 (3.5 %) due to relevant comorbidities/treatment with other immunosuppressants. 62 patients were included in the final analysis. At ocrelizumab start, mean age was 62.1 +/- 8.7 years and median EDSS was 7.0 (range 6.5 to 9.5). Ocrelizumab was started in 26 of the included 62 patients (41.9 %) because of objective clinical disease worsening, in 17 (27.4 %) because of subjective worsening, in 8 (12.9 %) to prevent future progression. 32 patients (51.6 %) continued ocrelizumab throughout the study period, with average length of ocrelizumab use of 36.5 +/- 17.0 months. 29 patients (46.8 %) experienced no side effects during the study period. 29 (46.7 %) patients discontinued treatment, and of those, 9 (31.0 %) cited more than one reason for discontinuation: 17 (58.6 %) cited side effects, 12 (41.4 %) cited progression/lack of benefit, 6 (20.7 %) cited the Covid19 pandemic, and 1 (3.4 %) cited financial issues as a reason for discontinuation. Over the course of the study, 16 (25.8 %) patients had disability worsening by EDSS, 5 (8.1 %) had disability improvement, and 41 (66.1 %) remained stable, with a median end EDSS of 7.0 (range 6.5 to 9.5). Importantly, 18 patients (29.0 %) reported subjective disease stability while on ocrelizumab.

CONCLUSIONS:

Ocrelizumab may lead to disease stabilization in a subset of highly disabled MS patients, but possible benefits need to be carefully balanced against the incidence of adverse events in this high-risk patient population.

项与维妥珠单抗相关的新闻（医药）

2024-08-27

·PRNewswire

JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma

SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China has approved the supplemental Biological License Application (sBLA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product Carteyva® (relmacabtagene autoleucel injection) for the treatment of adult patients with relapsed or refractory Mantle Cell Lymphoma (r/r MCL). This is the third marketing approval on Carteyva® submitted by JW Therapeutics, and is the first cell therapy product approved in China for the treatment of patients with r/r MCL. Carteyva® was granted, by NMPA, Breakthrough Therapy Designation in Mar 2022, as well as Priority Review in Dec 2023. MCL is a heterogeneous B cell non-Hodgkin lymphoma which is currently incurable with existing therapies[1]. MCL, associated with a poor prognosis, mainly occurs in elderly men who were not diagnosed until advanced stage[2]. Significant progress has been made in the last decade as the treatment paradigm has shifted from traditional chemoimmunotherapy toward targeted therapies such as bruton tyrosine kinase inhibitors (BTKi). Despite the use of BTKi in r/r MCL has improved their survival outcomes, many patients will ultimately relapse with shortened remission durations (6~10 months) [3]. Notwithstanding the above, there are still unmet medical needs for a safe, effective novel approach to overcome the limitations of current treatments of r/r MCL. The sBLA was supported by the clinical results from a single-arm, multi-center, pivotal study on Carteyva® in adult patients with r/r MCL in China. In the study, patients with r/r MCL who had been treated with a CD20-targeting antibody, anthracycline or bendamustine, or BTKis were included. After being treated with lymphodepleting chemotherapy, patients received Carteyva® (100×106 CAR+ T cells). As of August 7th, 2023, a total of 59 patients received Carteyva® infusion. Of 59 efficacy evaluable patients, Carteyva® demonstrated remarkable clinical responses achieving high rates of objective response rate (ORR) and complete response rate (CRR) (best ORR 81.36%, best CRR 67.80%) and the incidence of severe (grade ≥ 3) cytokine release syndrome (CRS) was 6.8%, the incidence of severe (grade ≥ 3) neurotoxicity (NT) was 6.8%. Sophia Yang, Senior Vice President and Head of Regulatory, Research & Development of JW Therapeutics, noted: "We are delighted to have a product that can deliver meaningful efficacy in this disease, nearly 70% of patients with r/r MCL have achieved complete remission after treatment with Carteyva®, and the overall safety data demonstrated that the treatment was generally well-tolerated. Carteyva® becomes the first commercial CAR-T cell product for the treatment of r/r MCL in China." References The consensus of the diagnosis and treatment of mantle cell lymphoma in China (2016 version). Chin J Hematol.2016, 37(9):735-741. Herrmann A, Hoster E, Zwingers T, et al. Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma[J]. Journal of Clinical Oncology, 2009, 27(4):511-518. Burkart M, Karmali R. Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors. J Pers Med. 2022 Mar 1;12(3):376. About Relmacabtagene Autoleucel Injection Relmacabtagene autoleucel injection (abbreviated as relma-cel, trade name for oncology indications: Carteyva®) is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics based on a CAR-T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company). Being the first product of JW Therapeutics, Carteyva® has been approved by the China National Medical Products Administration (NMPA) for three indications, including the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBLC) after two or more lines of systemic therapy, the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment (r/r FL), and the treatment of adult patients with relapsed or refractory mantle cell lymphoma ("r/r MCL") after two or more lines of systemic therapy including bruton tyrosine kinase inhibitors ("BTKi"), making it the first CAR-T product approved as a Category 1 biologics product in China. Currently, it is the only CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, priority review and breakthrough therapy designations. About JW Therapeutics JW Therapeutics (HKEx:2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Since its founding in 2016, JW Therapeutics has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and beyond, and to leading the healthy and standardized development of China's cell immunotherapy industry. For more information, please visit . Forward-Looking Statements The forward-looking statements are based on the management's expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described. Significant risks and uncertainties, include those discussed below and more fully described in Hong Kong Exchanges and Clearing Limited (HKEx) reports filed by the Company. Unless otherwise noted, the Company is providing this information as of the date it publicized, and expressly disclaims any duty to update information contained in the issues and relevant information, or provide any explanation. For detailed information, please visit the company website: . SOURCE JW Therapeutics

免疫疗法上市批准细胞疗法突破性疗法优先审批

2024-08-06

·PipelineReview

Indapta Therapeutics Announces FDA Clearance of IND for Phase 1 Trial of IDP-023 for Progressive Multiple Sclerosis

Company’s g-NK Cell Therapy Has Multiple Potential Mechanisms That Could Impact Biology of Multiple Sclerosis HOUSTON, TX & SEATTLE, WA, USA I August 06, 2024 I Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated cell therapies for the treatment of cancer and autoimmune diseases, today announced that the U.S. FDA has cleared the IND for the company’s Phase 1 clinical trial of its g-natural killer (g-NK) cell therapy, IDP-023, in progressive multiple sclerosis (MS). Stanford University and the University of California, San Francisco (UCSF) will lead the clinical trial. People with progressive MS will receive IDP-023 in combination with the anti-CD20 monoclonal antibody, ocrelizumab. The study will interrogate the biologic effects of IDP-023 using a translational program developed in collaboration with Stanford and UCSF. “I am excited to participate in this clinical trial because of the multiple potential mechanisms by which g-NK cells may impact the biology of MS,” said Dr. Lawrence Steinman, Professor of Medicine and Principal Investigator at Stanford. “In addition to being able to achieve B cell depletion by combining with a B cell directed monoclonal antibody, g-NK cells have the ability to kill HLA-E expressing autoreactive T and B cells. In addition, g-NK cells have potent anti-viral activity, and therefore may also address the Epstein Barr Virus reservoir that contributes to the disease pathogenesis.” Indapta is currently conducting a Phase 1/2 trial of IDP-023 in patients with non-Hodgkin’s lymphoma and multiple myeloma. “This IND is another in a series of milestone achievements from our team in recent months,” said Dr. Mark Frohlich, CEO of Indapta. “We look forward to the second half of the year during which we plan to initiate this trial and continue progress with our ongoing Phase 1/2 trial of IDP-023 in patients with hematologic cancers, where we have seen very encouraging responses to date.” Indapta’s Proprietary g-NK Cell Therapy Indapta’s universal, allogeneic NK cell therapy platform consists of a potent subset of naturally occurring NK cells, known as “g minus” NK cells, or “g-NK” cells. G‑NK cells arise from epigenetic changes resulting from exposure to cytomegalovirus (CMV). To generate IDP-023, Indapta preferentially expands g-NK cells from healthy donors, with low donor to donor variability. IDP-023 has several differentiated mechanisms of killing target cells without the need for genetic engineering, including highly robust antibody-dependent cell mediated cytotoxicity (ADCC), the targeting of HLA-E expressing cells via the NKG2C receptor, and the inherent anti-viral activity of g-NK cells. Indapta’s g-NK can release dramatically more immune activating cytokines and cell-killing compounds than conventional NK cells. In preclinical studies, IDP-023 has demonstrated more potent and durable antitumor activity when combined with cancer targeting monoclonal antibodies as compared to conventional NK cells. (Bigley et al., Blood Advances 2021, https://doi.org/10.1182/bloodadvances.2020002440 ). g-NK cells in combination with a B cell targeting antibody can also deplete normal B cells from healthy donors or patients with autoimmune disease. About Indapta Therapeutics Indapta is a privately held company focused on developing and bringing to market a diverse pipeline of cell therapies to treat the still unmet medical needs of patients with blood and solid-tumor cancers as well as autoimmune diseases. The company’s proprietary robust platform of naturally occurring g-NK cells is specifically designed to create best-in-class, highly potent, more accessible, and scalable cell therapies. For more information, please visit www.indapta.com . SOURCE: Indapta Therapeutics

细胞疗法临床申请免疫疗法临床1期

2024-08-06

·Business Wire

HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics

STAMFORD, Conn.--( BUSINESS WIRE )--HealthCare Royalty (“HCRx”), in conjunction with funds managed by Blue Owl Capital (“Blue Owl”), has entered into a $250 million term loan facility (the “Initial Term Loan”) with TG Therapeutics, Inc. (“TG”, NASDAQ: TGTX), a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In January 2023, TG launched BRIUMVI® (ublituximab-xiiy), an anti-CD20 monoclonal antibody for the treatment of relapsing forms of multiple sclerosis (MS), which generated $89 million of U.S. net revenue in 2023. HCRx and Blue Owl funded the $250 million Initial Term Loan at closing with each party providing $125 million. The Initial Term Loan will mature on August 2, 2029. An additional facility of up to $100 million is available at the mutual option of TG and HCRx / Blue Owl. “We have been impressed with TG Therapeutics’ launch of BRIUMVI over the past 18 months,” stated Clarke B. Futch, Founder, Chief Executive Officer and Chairman at HCRx. “We believe our loan investment is well collateralized and provides TG Therapeutics with meaningful capital to support its business objectives.” “We are pleased to invest in TG Therapeutics as it continues to demonstrate strong commercial momentum with BRIUMVI,” said Sandip Agarwala, Managing Director at Blue Owl. “This loan investment is a great example of our scaled and structurally flexible approach in the life sciences sector.” About HealthCare Royalty HealthCare Royalty is a leading royalty acquisition company focused on commercial or near-commercial biopharmaceutical products. With offices in Stamford, Conn., San Francisco, Boston and London, HCRx has invested $5+ billion in over 85 biopharmaceutical products since inception. For more information, visit https://www.hcrx.com . HEALTHCARE ROYALTY® and HCRx® are registered trademarks of HealthCare Royalty Management, LLC. About Blue Owl Blue Owl (NYSE: OWL) is a leading asset manager that is redefining alternatives. With over $192.2 billion in assets under management as of June 30, 2024, we invest across three multi-strategy platforms: Credit, GP Strategic Capital, and Real Estate. Anchored by a strong permanent capital base, we provide businesses with private capital solutions to drive long-term growth and offer institutional investors, individual investors, and insurance companies differentiated alternative investment opportunities that aim to deliver strong performance, risk-adjusted returns, and capital preservation. Together with over 820 experienced professionals, Blue Owl brings the vision and discipline to create the exceptional. To learn more, visit www.blueowl.com .

并购

100 项与维妥珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09031	维妥珠单抗	-	DB05656

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
癌症	临床2期	美国	Takeda Pharmaceutical Co., Ltd.	2011-08-01
癌症	临床2期	阿根廷	Takeda Pharmaceutical Co., Ltd.	2011-08-01
癌症	临床2期	加拿大	Takeda Pharmaceutical Co., Ltd.	2011-08-01
癌症	临床2期	捷克	Takeda Pharmaceutical Co., Ltd.	2011-08-01
癌症	临床2期	德国	Takeda Pharmaceutical Co., Ltd.	2011-08-01
癌症	临床2期	匈牙利	Takeda Pharmaceutical Co., Ltd.	2011-08-01
癌症	临床2期	意大利	Takeda Pharmaceutical Co., Ltd.	2011-08-01
癌症	临床2期	墨西哥	Takeda Pharmaceutical Co., Ltd.	2011-08-01
癌症	临床2期	波兰	Takeda Pharmaceutical Co., Ltd.	2011-08-01
癌症	临床2期	西班牙	Takeda Pharmaceutical Co., Ltd.	2011-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ECTRIMS2023	N/A	RRMS	-	anti-CD20 monoclonal antibody	範觸鹽選壓衊網遞壓繭(淵製鏇壓憲衊願襯艱積) = 鏇淵淵襯窪窪遞鑰製獵鑰醖築廠製遞範醖鑰築 (鏇襯夢選願獵衊鏇齋獵 )	积极	2023-09-30
				anti-CD20 monoclonal antibody	範觸鹽選壓衊網遞壓繭(淵製鏇壓憲衊願襯艱積) = 鏇製簾積鹽廠衊鏇繭鬱鑰醖築廠製遞範醖鑰築 (鏇襯夢選願獵衊鏇齋獵 )
ECTRIMS2022	N/A	anti-CD20 IgG1 monoclonal antibodies	57	Ocrelizumab 300mg	選鏇鏇糧鬱膚築範鹹齋(鑰鹹膚糧憲築鹹鬱艱鏇) = 膚顧鑰鑰醖網艱糧鬱鏇鑰醖繭廠壓糧選鹹醖範 (壓繭壓鹽衊鹹壓餘齋簾 ) 更多	积极	2022-10-12
				Ocrelizumab 600mg	選鏇鏇糧鬱膚築範鹹齋(鑰鹹膚糧憲築鹹鬱艱鏇) = 顧積鏇鏇淵廠獵壓願簾鑰醖繭廠壓糧選鹹醖範 (壓繭壓鹽衊鹹壓餘齋簾 ) 更多
ECTRIMS2022	N/A	RRMS CD20	-	Anti-CD20 mAb treated patients with RRMS	繭鹹艱餘醖蓋壓艱廠鹹(構膚壓鏇鬱壓簾構夢構) = 製獵醖觸範製淵製積積膚遞廠鬱選網鬱鹹選觸 (鏇鹽選遞築壓憲鹽築鏇 ) 更多	-	2022-10-12
				anti-CD20 monoclonal antibody	繭鹹艱餘醖蓋壓艱廠鹹(構膚壓鏇鬱壓簾構夢構) = 觸蓋範觸壓製窪膚蓋鬱膚遞廠鬱選網鬱鹹選觸 (鏇鹽選遞築壓憲鹽築鏇 ) 更多
ACTRIMS2020	N/A	-	-	anti-CD20 monoclonal antibody	襯願願夢鏇顧鬱鹽鬱糧(觸範鹽憲蓋衊獵願憲顧) = 醖醖齋簾繭構餘築觸鏇鏇構壓遞糧糧廠齋窪顧 (衊餘構廠憲構淵鏇餘餘 ) 更多	-	2020-05-11
				anti-CD20 monoclonal antibody	襯願願夢鏇顧鬱鹽鬱糧(觸範鹽憲蓋衊獵願憲顧) = 築網積餘憲壓築鏇蓋鏇鏇構壓遞糧糧廠齋窪顧 (衊餘構廠憲構淵鏇餘餘 ) 更多
FP208 (ERA2019)	N/A	ANCA相关性血管炎	242	Mabthera	鹽構淵選鏇遞艱膚廠窪(網繭願鹹窪獵襯艱構壓) = One episode of anaphylaxis was reported with Mabthera 鬱願鹽繭遞繭艱簾艱膚 (齋鏇積艱遞積範選夢窪 ) 更多	积极	2019-06-13
				Truxima
NCT00547066 (Pubmed \| Haematologica) 人工标引	临床1/2期	免疫性血小板减少症 CD20 Positive	50	Veltuzumab	簾壓鬱艱糧範糧築窪網(遞艱蓋積簾鬱壓製襯網) = transient，mild to moderate 憲醖鬱鹽範窪壓衊積鹹 (衊鹽鏇積顧鹽顧鑰繭鑰 )	积极	2016-11-01
NCT00546793 (Pubmed \| Leuk Lymphoma) 人工标引	临床1期	慢性淋巴细胞白血病	21	veltuzumab	淵淵鏇淵製構築構鏇顧(網淵範廠餘顧築願艱範) = 餘淵窪築壓艱顧廠蓋積醖糧鏇築積構衊鹽鹹製 (餘顧積鑰觸窪壓膚齋憲 ) 更多	积极	2016-01-01
NCT00989586 (Pubmed \| Int J Radiat Oncol Biol Phys) 人工标引	临床1/2期	B细胞淋巴瘤	35	milatuzumab+veltuzumab	鹽鑰膚廠鹽鹹築築願鏇(廠範齋遞繭夢壓範獵鑰) = 簾鏇艱廠窪憲鬱淵構壓範遞願網繭糧齋顧遞糧 (憲膚壓觸鑰鹹廠醖壓蓋 ) 更多	积极	2015-06-01
				Veltuzumab 200 mg/m(2) weekly + Milatuzumab 16 mg/kg weekly	-
NCT00546793 (Pubmed \| Haematologica)	临床1/2期	惰性非霍奇金淋巴瘤	17	80 mg veltuzumab	顧蓋遞鬱鬱窪顧鏇繭願(構餘鹹獵製鏇夢願觸製) = 願壓糧鏇製齋鹹餘齋範壓壓壓窪憲鬱遞構鹽積 (醖製餘鬱糧蓋淵構築顧 ) 更多	积极	2011-04-01
				160 mg veltuzumab	顧蓋遞鬱鬱窪顧鏇繭願(構餘鹹獵製鏇夢願觸製) = 製範鹹築鬱簾壓簾襯繭壓壓壓窪憲鬱遞構鹽積 (醖製餘鬱糧蓋淵構築顧 )